 Patent Application Title |
Patent App Num. |
Date |
 Novel triazinedione derivatives as gabab receptor modulators | 20130123262 | 20130516 |  The present invention provides novel compounds of formula I wherein W1, W2, W3, W4, W5, B, X1, X2, X3, X4, X5, E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABAB”) positive allosteric modulators (enhancers), which are useful to provide methods of treating or preventing diseases or disorders, including treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, panic disorder, posttraumatic stress disorders, urge urinary incontinence, gastroesophageal reflux disease, transient lower oesophageal sphincter relaxations, functional gastrointestinal disorders and irritable bowel syndrome.
... | | Compositions and methods for treatment of inflammatory bowel disorders and intestinal cancers | 20130123264 | 20130516 |  Methods of using the compositions to treat intestinal and bowel diseases, and intestinal cancers, and methods of improving one or more physiological parameters of intestinal luminal integrity including, but are not limited to, reduced proliferation for example in the intestinal crypts, reduced apoptosis for example at the luminal surface, and induction of downstream effectors of PKG-mediated signaling are also disclosed.
... | | Absorbent article and a method of forming and using | 20130123733 | 20130516 |  An absorbent article is disclosed which is designed to protect both a wearer's penis and scrotum from any bowel movement waste. The absorbent article includes a liquid-impermeable outer cover with a first absorbent and a second absorbent longitudinally positioned on the outer cover. The first absorbent has a first end and a second end, and the second absorbent has a first end and a second end. The second end of the first absorbent is spaced apart from the first end of the second absorbent. A liquid permeable bodyside liner covers the first absorbent and the second absorbent. The absorbent article further includes a fenestrated flap disposed between the first and second absorbents. The fenestrated flap has a first end which is bonded directly to the outer... | | Oral administration forms for controlled release of rifampicin for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract | 20130115286 | 20130509 |  Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.
... | | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | 20130116199 | 20130509 |  The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
... | Subscribe to updates on this page: Bowel RSS  | | Treatment of irritable bowel syndrome | 20130116334 | 20130509 | | A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
... | | Sit-up excerciser having secondary purpose of promoting bowel movement | 20130109550 | 20130502 | | A sit-up exerciser having a secondary purpose of promoting a bowel movement. Two pivot plates correspondingly pivot, a waist support plate is disposed between the pivot plates to prevent the waist from slipping, and the pivoting angle of the pivot plates can be easily adjusted, so that a person who needs to exercise his or her waist can easily exercise it while having his/her bowel movement facilitated in order to promote the health. The pivoting angle of the pivot plates can be easily adjusted to control the intensity of the exercise, the pivoting speed of the pivot plates can be adjusted to be fast or slow, the temperature of the pivot plates can be adjusted from room temperature up to 70° C. so that the temperature... | | Electronic discriminating device for body exudate detection | 20130110061 | 20130502 | | An electronic discriminating device incorporating a non-contact electronic sensor array, a controller, and a signaling device that may indicate the presence of urine and/or bowel movement is disclosed. In particular, the electronic discriminating device can discriminate between an insult of urine only and an insult containing bowel movement. The device can then generate different alerts based on the type of insult. The electronic discriminating device may also emit a signal at or near the opening of an absorbent article or transmit the alert wirelessly to a radio, computer device, or smartphone.
... | | Absorbent article with sensor array for body exudate detection | 20130110063 | 20130502 | | An absorbent article incorporating a non-contact electronic sensor array that may indicate the presence of a body exudate is disclosed. In particular, the absorbent article includes at least a non-contact electronic sensor array that may include one or more gas sensors, a controller and a signaling device. The signaling device is capable of alerting a user (wearer or caregiver) that an insult of urine or bowel movement has occurred. In accordance with the present disclosure, various attachment mechanisms are disclosed for attaching the non-contact electronic sensor array, controller and signaling device to an absorbent article.
... | | Probiotic composition for use in the treatment of bowel inflammation | 20130101566 | 20130425 | | The present disclosure is directed to compositions comprising Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. This composition is useful in the treatment of gastrointestinal diseases or conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, or abdominal distension and bloating.
... | | Use of tight junction antagonists to treat inflammatory bowel disease | 20130102547 | 20130425 | | The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.
... | | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | 20130096071 | 20130418 | | The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
... | | Compositions and methods of treatment for inflammatory diseases | 20130096093 | 20130418 | | Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
... | Subscribe to updates on this page: Bowel RSS | | Imidazopyridine compounds, compositions and methods of use | 20130096104 | 20130418 | | The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy, as an inhibitor of TYK2 kinase and conditions related, such as inflammatory illnesses, inflammatory bowel disease or psoriasis.
... | | Heterocyclic compounds and their uses | 20130096134 | 20130418 | | Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia... |
| Methods and devices for detecting bowel perforation | 20130096399 | 20130418 | | The present disclosure relates to methods and devices to detect perforation of the bowel, for example, resulting from surgical procedures, such as laparoscopy, diagnostic procedures, such as colonoscopy, medical conditions, such as diverticulitis, and trauma. The present disclosure also relates to filtration systems and electrical connector assemblies for use in the methods and devices.
... | | Method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof | 20130089605 | 20130411 | | Disclosed is a commercially viable asiaticoside composition having at least 99% purity that is derived from plant Centella asiatica and a manufacturing process thereof. Also disclosed is a method and the models for oral administration of therapeutically effective amounts of the asiaticoside composition for treatment of Inflammatory Bowel Diseases such as Ulcerative colitis, Crohn's disease and associated complications of inflammatory bowel diseases such as hemorrhoids, anal fissures, fistulas. Also disclosed is a method and model for oral administration of therapeutically effective amounts of the asiaticoside composition for treatment of Helicobacter Pylori, as well as a method and the models for oral administration of therapeutically effective amounts of the asiaticoside composition for prevention of colon cancer, gastric diseases and gastric carcinoma.
... | | Heterocyclic compounds and their uses | 20130090323 | 20130411 | | Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL)... | | Polymorphic forms of rifaximin | 20130090348 | 20130411 | | Provided for in the instant application are two additional polymorphic forms of rifaximin; namely substantially pure APO-I and APO-II. Also provided are processes for preparing substantially pure APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.
... | | Therapeutic antisense oligonucleotide compositions for the treatment of inflammatory bowel disease | 20130090368 | 20130411 | | Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTGGCATCCGTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.
... | | Antagonists for the prevention of treatment of inflammatory bowel disease, and more particularly of crohn's disease | 20130084292 | 20130404 | | An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory... | | Method and mixture for treating and preventing inflammatory bowel disease | 20130085118 | 20130404 | | A method and a mixture for treating and preventing the inflammatory bowel disease (IBD) by applying a predetermined therapeutically effective amount of a mixture of hyaluronic acid to individuals is disclosed. The mixture includes at least two different average molecular weight hyaluronic acids (Mw) with different rheology to gain a hyaluronic acid with the proper adhesion property, functions of tissue scaffold and insulation and treatment time, in order to treat and to prevent IBD (inflammatory bowel disease) includes ulcerative colitis, Crohn's disease or wound healing in stomach and intestine, thus to achieve the prompt treatment and to prolong the effect.
... | | Heterocyclic compounds and their uses | 20130085131 | 20130404 | | Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia... | | Heterocyclic compounds and their uses | 20130085151 | 20130404 | | Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL)... | | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | 20130085275 | 20130404 | | (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial... | | Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors | 20130086701 | 20130404 | | A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers.
... | | Biomarkers for ulcerative colitis and crohn's disease | 20130079245 | 20130328 | | The present invention provides compositions and their use in diagnosing ulcerative colitis, Crohn's Disease, and inflammatory bowel disease.
... | | Heterocyclic compounds and their uses | 20130079342 | 20130328 | | Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell... | | Selective termination of stimulation to deliver post-stimulation therapeutic effect | 20130079840 | 20130328 | | In some examples, electrical stimulation is delivered to a patient such that selective termination of the stimulation causes a therapeutic effect in the patient after termination of the electrical stimulation to the patient. The electrical stimulation may be insufficient to produce a desired therapeutic effect in the patient during stimulation, but sufficient to induce a post-stimulation desired therapeutic effect following termination of the stimulation. In some examples, the electrical stimulation may be sub-threshold electrical stimulation. In some examples, the desired therapeutic effect may alleviate bladder dysfunction, bowel dysfunction, or other disorders. The stimulation may be selectively terminated in response to one or more therapy trigger events to induce the post-stimulation therapeutic effect.
... | | Auscultation training system | 20130071826 | 20130321 | | An auscultation training system is disclosed comprising a half-body mannequin with speakers providing heart, lung, bowel and bruit sounds in the correct anatomical positions for student training of auscultation with a standard stethoscope. An integrated computer system provides the tools for training and assessing students. Synchronized phonocardiograms and a palpable carotid pulse accompany heart sounds. Sounds can be played and auscultated simultaneously to simulate a live patient, or played and auscultated separately for teaching purposes. The system may be accessed online using a virtual mannequin and stethoscope for viewing and listening to heart, lung, bowel and bruit sounds.
... | | Inflatable stomal implant | 20110015475 | 20110120 | | A stomal implant comprising a longitudinal portion configured to envelop at least a section of the bowel or ileal conduit, said longitudinal portion comprising: a proximal end for positioning at a stomal opening; a distal end for positioning within an abdomen; and a reversibly pressure-exerting device providing an ascending pressure gradient from the distal end to the proximal end, such that pressure exerted at the proximal end provides complete closure of the bowel or urethra.
... | | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | 20110015230 | 20110120 | | The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
... | | Indolinone compound | 20110009379 | 20110113 | | [Means for Solution] The present inventors have extensively studied compounds having TRPA1 channel activation activity, and confirmed that an indolinone compound has a TRPA1 channel activation activity, and thus completed the present invention. The indolinone compound of the present invention has a TRPA1 channel activation activity and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating constipation-type irritable bowel syndrome, atonic constipation and/or functional gastrointestinal disorder or the like.
... | | Glucagon-like peptide-2 analogs | 20110009320 | 20110113 | | Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
... | | Methods of treating or preventing inflammatory diseases of the intestinal tract | 20110008476 | 20110113 | | The present invention relates to a glucan derived from yeast having a beta-(1, 3)-backbone with one or more beta-(1, 3)-side chains linked thereto for use in the treatment or prevention of inflammatory bowel disease and related diseases of abnormal bowel function in an animal, in particular to such uses employing a soluble glucan, e.g. from Saccharomyces cerevisiae, preferably when administered orally. The invention also relates to alternative treatments of inflammatory bowel disease and related diseases of abnormal bowel function utilising meal or protein derived from Asteraceae.
... | | Prebiotic compositions | 20110003768 | 20110106 | | The present invention concerns nutritional compositions comprising oligosaccharides for controlling inflammatory bowel disease and related disorders, such as diarrhoea and constipation.
... | | Multimeric vla-4 antagonists comprising polymer moieties | 20110002876 | 20110106 | | Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
... | | Heterocyclic compounds and their uses | 20100331306 | 20101230 | | Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL)... | | Heterocyclic compounds and their uses | 20100331293 | 20101230 | | Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL)... | | Phospholipid compositions and uses thereof | 20100331281 | 20101230 | | We have discovered that phospholipids diundecanoyl (C11:0-C11:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids and structurally related lipids. Also featured are methods of treating metabolic disorders and inflammatory bowel disease, lowering blood glucose levels, and increasing LRH-1 receptor activity in a subject by administration of these lipids.
... | | Gastroresistant pharmaceutical formulations containing rifaximin | 20100330129 | 20101230 | | The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
... | | Methods of using btl-ii proteins | 20100330104 | 20101230 | | The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
... | | Novel heterocycles | 20100329998 | 20101230 | | Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases.
... | | Treatment and prevention of inflammatory diseases and autoimmune diseases | 20100329985 | 20101230 | | The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used.
... | | Humanized anti-alpha 9 integrin antibodies and the uses thereof | 20100329980 | 20101230 | | The present invention provides humanized antibodies that immunospecifically recognize human α9 integrin. Some of these antibodies inhibit the biological functions of the α9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with α9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
... | | Medicament for preventive and/or therapeutic treatment of bowel disease | 20100324134 | 20101223 | | A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.
... | | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient | 20100324057 | 20101223 | | which is a sphingosine-1-phosphate receptor agonist or a pharmaceutically acceptable salt or hydrate thereof are a therapeutic agent or prophylactic agent for an inflammatory bowel disease comprises.
... | | Inhibitors of parp activity and uses thereof | 20100323974 | 20101223 | | The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5′-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy,... | | Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 | 20100322980 | 20101223 | | The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive... | | Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field | 20100317719 | 20101216 | | The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
... | | Diagnostic test | 20100316992 | 20101216 | | Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.
... | | Medical bed structure | 20100313357 | 20101216 | | A medical bed structure includes a bed frame. The bed frame is provided with a plurality of spray nozzles on its edge. The bottom of the bed frame is formed with a discharge hole and a cleaning set on the discharge hole. The spray nozzles are capable of spraying water for cleaning. The discharge hole is adapted to discharge feces. The cleaning set is adapted to clean the anus of the patient after having a bowel movement. The present invention provides a patient who lies in bed for a long period of time to take a bath and to clean the feces automatically.
... | | Disposable absorbent article with masking topsheet having one or more openings providing a passageway to a void space | 20100312210 | 20101209 | | The present invention relates to a disposable absorbent article, such as a diaper, training pants, adult incontinence article, having a specific topsheet with an opening to receive bowel movement waste (BM) and which is such that it masks the waste present underneath said topsheet. The topsheet is air permeable and it has a uniform pore size distribution with small pores only and it has a low surface energy and therefore an alcohol repellency of at least 7, typically at least 9 or even preferably 10.
... | | Bicyclosulfonyl acid (bcsa) compounds and their use as therapeutic agents | 20100311741 | 20101209 | | This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-α, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in the inhibition of TACE, and in the treatment of conditions that are ameliorated by the inhibition of... | | Device, system and method for examining a body lumen | 20100305415 | 20101202 | | An in-vivo examining device, system and method for identifying the presence of strictures in the small bowel are provided. The in-vivo examining device includes a monitoring mechanism that becomes deactivated when exposed to in-vivo substances native to the small bowel or the colon, and a degradable device body that includes at least a first body portion which degrades at a slow rate when exposed to in-vivo substances native to the small bowel and at a fast rate when exposed to in-vivo substances native to the colon. The degradation of the degradable device body exposes the monitoring mechanism to substances native to the small bowel or the colon and thus indicates whether the examining device has safely passed through the small bowel or whether it is retained... | | Pharmaceutical composition | 20100305178 | 20101202 | | A topical composition comprises at least 5-wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, and anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
... | | Slowly fermentable soluble dietary fiber | 20100303953 | 20101202 | | The embodiments described herein provide a method for improving bowel health by increasing short chain fatty acid concentration in the colon of a mammal including administering to the mammal a composition having from about 0.1 grams to about 50 grams of a treated bran product. After administration, the treated bran product results in an increased short chain fatty acid production during fermentation in the colon as compared to untreated bran fermented in the colon.
... | | Tablet with remedial composition and methods for treating medical disorders and ailments | 20100303904 | 20101202 | | The invention discloses a pharmaceutical composition useful for treatment and prevention of medical disorders and ailments. The aforesaid composition comprises active ingredients comprising; Turmeric extract, Turmeric powder, Selenium or source of Selenium, especially Selenomethionine, and Green tea extract. The disclosed pharmaceutical composition is especially adapted for treatment of inflammatory bowel disease (IBD) and colorectal cancer (CRC).
... | | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | 20100303782 | 20101202 | | A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the disclosure may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.
... | | Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof | 20100298232 | 20101125 | | The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.
... | | Methods of treating diarrhea caused by small intestinal bacterial overgrowth | 20090325994 | 20091231 | | Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit... | | Indazolyl derivatives useful as potassium channel modulating agents | 20090325989 | 20091231 | | Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular respiratory diseases, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, autism, ataxia, traumatic brain injury, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, anxiety, depression, mania, mood disorders, dementia, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, spasticity, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, irritable bowel syndrome, immune suppression, migraine and pain.
... | | Method for treating inflammatory diseases using rho kinase inhibitor compounds | 20090325960 | 20091231 | | This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, edema and inflammation. Particularly, this invention is directed to methods of treating inflammatory diseases or conditions such as rheumatoid arthritis and inflammatory bowel disease. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a compound of a novel rho kinase inhibitor compound to treat the disease.
... | | Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic | 20090324736 | 20091231 | | The present invention relates to formulations and kits for the treatment of bowel disease, to their use in medicinal preparations and to therapeutic methods thereof.
... | | Uses of analogs of 3-o-acetyl-11-keto-beta-boswellic acid | 20090318551 | 20091224 | | These compounds exhibited 5-Lipoxigenase inhibitory properties and these compounds may be used in pharmaceutical compositions for therapeutic applications against a variety of inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia. These compounds also inhibited the growth of Brine Shrimp in cultures, which may be considered as a positive indication for cytotoxicity and antitumor activity.
... | | Oligomeric compounds for the modulation of survivin expression | 20090318362 | 20091224 | | Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
... | | Electronic stethoscope system | 20090316925 | 20091224 | | An electronic stethoscope head includes a head member having a contact surface for contact with a patient's body, a transducer in the head member, and an adhesive on the contact surface. A processing system for an electronic stethoscope includes a conditioning circuit configured to receive a transducer signal from a transducer and to be capable of amplifying and/or filtering the transducer signal, to yield a conditioned signal. There is also a signal processor system configured to subject the conditioned signal to an audio editing process. Bodily sounds are detected by applying an electronic stethoscope head a patient's body; generating a patient sonograph of the patient's bodily sounds; and comparing the patient sonograph to a reference sonograph. An electronic stethoscope system may include an accessory device and... | | Method for management of diarrhea | 20090312358 | 20091217 | | The present invention is directed to methods of treatment and/or management of diarrhea, such as chronic diarrhea using sequential administration of opioid agonists to suppress gut mobility and opioid antagonists to reverse the effect to controllably allow bowel movements. The agonists and antagonists are administered with a time interval in between the administration or between the release of the drugs from a pharmaceutical composition. The invention is further directed to methods of controlling, treating or managing side effects caused by the opioid agonists, specifically the side effects resulting from mast cell activation and/or granulation.
... | | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders | 20090312259 | 20091217 | | This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
... | | Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds | 20090312243 | 20091217 | | Inhibitors of angiogenesis are disclosed as being useful therapeutics for treating various aspects of inflammatory bowel disease, in particular Crohn's Disease. A method for decreasing the magnitude of intestinal inflammation or inflammatory infiltrate in bowel tissue, a method for lowering systemic or gut-associated levels of a proinflammatory cytokine in a subject, a method for reducing microvessel density in fixed bowel tissue sections and a method for treating an inflammatory bowel disease are disclosed. Preferred agents to achieve the foregoing are pentapeptides that include Pro-His-Ser-Cys-Asn (SEQ ID NO:1) and variants or derivatives thereof.
... | | O-glycans as diagnostic markers for inflammatory bowel disease | 20090311707 | 20091217 | | The present invention provides diagnostic methods for inflammatory bowel disorders (e.g., Crohn's disease or ulcerative colitis) comprising assessing expression, structure and/or function of O-glycans in a sample from a subject, as well as antibodies to such molecules.
... | | Splice variants of human il-23 receptor (il-23r) mrna and use of a delta 9 isoform in predicting inflammatory bowel diseases | 20090311694 | 20091217 | | There is disclosed the cloning and identification of human IL-23R splice variants caused by alternative splicing of the IL-23R mRNA in human. Alternative mRNA forms occur through skipping one, multiple full exons or partial exons, within the IL-23R gene. A total of twenty-five (25) different IL-23R transcripts were identified. A novel exon deletion (exon 9) isoform in the interleukin 23 receptor is disclosed, denoted as Δ9. The present application also describes a quantitative assay to measure different IL-23R isoform. Detection of Δ9 isoform of IL-23R is predominantly present in colon and cervical tissues. A decrease in Δ9 is observed in inflamed colon tissues in Crohn's patients. There is disclosed a method of predicting Crohn's disease by measuring Δ9 isoform of IL-23R.
... | | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders | 20090311261 | 20091217 | | The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.
... | | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders | 20090311260 | 20091217 | | The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.
... | | Treatment of inflammatory bowel disease | 20090311228 | 20091217 | | A method of treating inflammatory bowel disease (IBD) comprises collecting regulatory T cells in an activated or non-activated state from a patient's sentinel lymph nodes draining bowel segments with or without IBD, optionally activating the cells by contacting them with a cytokine and an antigen extract obtained from an inflamed bowel segment, expanding the T cells in vitro, and re-infusing the expanded T cell to the patient. Also disclosed are methods for obtaining sentinel nodes, for expanding T cells, for re-establishing the TH1/TH2 balance in the patient suffering from Crohn's disease, and corresponding uses of the expanded T cells, the cytokine and of antigen extract, as well as of correspondingly activated and expanded T cells.
... | | Synthesis of tegaserod or a salt thereof | 20090306170 | 20091210 | | The present invention relates to a novel process for the synthesis of 1-((5-methoxy-1H-indol-3-yl)methyleneamino)-3-pentyl-guanidine, commonly known as tegaserod, which is used as a gastroprokinetic, and salts thereof. The present invention also relates to tegaserod and salts thereof having an HPLC purity of about 95% or more. The present invention further relates to pharmaceutical compositions comprising tegaserod or a salt thereof, second medical uses of tegaserod or a salt thereof, and methods of treating or preventing irritable bowel syndrome using tegaserod or a salt thereof.
... | | Muscarinic receptor antagonists | 20090306134 | 20091210 | | Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.
... | | Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use | 20090306070 | 20091210 | | The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.
... | | Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease | 20090306045 | 20091210 | | The present invention relates to the use of glycogen synthase kinase 3(GSK3) inhibitors, especially inhibitors of GSK-3α, GSK-3β and GSK-3β2, preferably, inhibitors of GSK-3β, in patients having autoimmune diseases and/or immune dysfunction/dysregulation to induce immune tolerance. Inhibition of GSK leads to activation of a pathway of dendritic cell maturation which leads to a dendritic phenotype which attenuates, rather than induces, immune responses. The immune responses and mature dendritic cells produced by the method of the present invention redirect or attenuate the immune response in individuals, thus leading to effective therapies for a number of autoimmune diseases and/or diseases of immune dysfunction/dysregulation (immune inflammatory diseases), including systemic lupus erythematosus (SLE), autoimmune diabetes (type I diabetes mellitus), asthma, rheumatoid arthritis, inflammatory bowel disease, among numerous others.
... | | Microbial markers of inflammatory bowel disease | 20090305267 | 20091210 | | The present invention relates to bacterial serine protease autotransporter (SPATE) and Antigen 43 (Ag43) and their various uses relating to inflammatory bowel disease (IBD), specifically in the diagnosis of IBD and the screening of potential agent for treating IBD. The invention also relates to methods for cultivating and identifying enteric microbes.
... | | Aerosol and injectable formulations of nanoparticulate benzodiazepine | 20090304801 | 20091210 | | Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam, and at least one surface stabilizer. The formulations are useful in the treatment of status epilepticus, treatment of irritable bowel syndrome, sleep induction, acute psychosis, and as a pre-anesthesia medication.
... | | Structure-analysis system, method, software arrangement and computer-accessible medium for digital cleansing of computed tomography colonography images | 20090304248 | 20091210 | | A system, method, software arrangement and computer-accessible medium for performing electronic cleansing of CT colonography images are provided. In this system, method, software arrangement and computer-accessible medium, the digital bowel cleansing can be performed to remove tagged bowel contents from the images. The digital bowel cleansing can apply a local shape analysis throughout the images and use a shape-based speed function to detect the folds and polyps structures while removing the tagged bowel contents region. The system, method, software arrangement and computer-accessible medium can enable a medical examiner to perform an accurate virtual colonoscopy on a patient, without the need for thorough patient preparation.
... | | Benzimidazolone derivatives | 20090298811 | 20091203 | | This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein. These compounds are useful in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain,... | | 5-ht3 receptor modulators, methods of making, and use thereof | 20090298809 | 20091203 | | Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.
... | | Use of charcoal for treating inflammatory conditions | 20090297499 | 20091203 | | The invention relates to the use of charcoal in the manufacture of an oral composition for the treatment of an inflammatory condition other than an inflammatory bowel disease and other than interstitial or other inflammation within the kidney.
... | | Proteins for use in diagnosing and treating infection and disease | 20090291884 | 20091126 | | The present invention describes a composition comprised on cystatin A and at least one histone used in diagnostic tools and for the treatment of diseases associated with reduced T helper cell counts such as HIV-1 infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, heumatoid arthritis, Alzheimer's disease, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease / irritable bowel syndrome, Crohn's disease, Psoriasis, Chronic obstructive pulmonary disease, System lupus erythematosus, transplant rejection and cancer.
... | | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | 20090285891 | 20091119 | | Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.
... | | Gut prosthetic | 20090281634 | 20091112 | | A prosthetic device for the intestine is disclosed that bypasses an enterocutaneous fistula so that the intestinal tract can properly function without bowel contents leaking onto the skin. The prosthetic device includes means to securely connect and seal it to the intestine, means to push bowel contents through it, and means to prevent the backflow of bowel contents through the digestive tract.
... | | Gut prosthetic | 20090281634 | 20091112 | | A prosthetic device for the intestine is disclosed that bypasses an enterocutaneous fistula so that the intestinal tract can properly function without bowel contents leaking onto the skin. The prosthetic device includes means to securely connect and seal it to the intestine, means to push bowel contents through it, and means to prevent the backflow of bowel contents through the digestive tract.
... | | Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases | 20090275634 | 20091105 | | The present invention relates to novel uses of antisense oligonucleotides targeted to the coding region of acetylcholinesterase (AChE) for treating inflammatory disorders other than inflammatory disorders of the central nervous system or the peripheral nervous system innervating voluntary muscles. More particularly, the present invention relates to uses of antisense oligodexoynucleotides targeted to AChE mRNA for treating inflammatory disease of the gastrointestinal tract including inflammatory bowel disease.
... | | Colonic delivery of active agents | 20080317666 | 20081225 | | Drug delivery devices that are orally administered, and that release active ingredients in the colon, are disclosed. In one embodiment, the active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam containing antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In another embodiment, the active agents are those that specifically treat colonic disorders, such as Chrohn's Disease, irritable bowel syndrome, ulcerative colitis, colorectal cancer or constipation. The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethyleneimine. The high crosslink density of the polyethyleneimine is believed to stabilize the pectin beads for a sufficient amount of time such that a substantial amount of the active ingredients can be administered... | | Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals | 20080317885 | 20081225 | | Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and/or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor,... | | Treatment of disorders and diseases of the colon | 20080318931 | 20081225 | | A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA).
... | | Colonic delivery therapeutic agents for inflammatory bowel disease | 20080319073 | 20081225 | | The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.
... | | Bifidobacterium in the treatment of inflammatory disease | 20080311080 | 20081218 | | A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
... | | Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors | 20080311097 | 20081218 | | The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
... | | Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists | 20080311179 | 20081218 | | and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with... | | Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders | 20080312215 | 20081218 | | are disclosed. Inhibition of CXCR3 activation is useful for treating disorders resulting from CXCR3-associated T-cell mediated function, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and diabetes, as well as in the prevention of allograft rejection. N-ethyl-1,4-diazepane-1-carboxamides in which R1 is substituted or unsubstituted arylalkyl and R3 is substituted or unsubstituted aryl are particularly preferred.
... | | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | 20080312234 | 20081218 | | This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
... | | Heterocyclic gaba-b modulators | 20080312291 | 20081218 | | The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein X1 and X2 are selected from 0 and N or S and N and R1, R2 and Y are as defined in the description. For example, R1 may be alkyl, alkoxy, thioalkoxy or aryl, R2 may be alkoxy and Y may be a carbonylamino-linked substituent containing an aryl... | | Imidazoles as gaba- b receptor modulators | 20080312305 | 20081218 | | The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description. For example, R1 may be alkyl or arylalkyl, R2 may be alkyl, R3 may be alkoxy and R4 may be a substituent containing an aryl group.
... | | Novel ligand of g protein coupled receptor protein and use thereof | 20080305110 | 20081211 | | The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and the ligand or a salt thereof; etc. The present invention is useful for screening agents for the prevention/treatment of, e.g., leukopenia, leukemia, lymphoma, malignant tumor, ulcerative colitis, rheumatoid arthritis, inflammatory bowel disorders, tonsil disorders, collagen disease, inflammatory disease, leukocytosis, heart failure, inherited muscle disorders, muscular dystrophy, neuromuscular degenerative disease, myocardial infarction, obesity, mellitus diabetes, hyperlipemia, arteriosclerosis, metabolic syndrome, thrombocytopenia, thrombocytosis, cancer, pulmonary edema, multiple organ failure, etc.
... | | Prevention, treatment, and amelioration of radiation induced enteritis | 20080306029 | 20081211 | | The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment of, for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, ladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof.
... | | Method and system for monitoring gastrointestinal function and physiological characteristics | 20080306355 | 20081211 | | A system and method for evaluating gastrointestinal motility and, optionally, other physiological characteristics (e.g., pulse rate) that can be effectively employed to acquire one or more signals associated with acoustic energy (i.e. sound) emanating from an abdominal region of a body and determine at least one gastrointestinal parameter or event based on the acoustic energy signal(s) is described. The gastrointestinal parameter can include a gastrointestinal event, including gastrointestinal mixing, emptying, contraction and propulsion, and gastrointestinal transit time, or a gastrointestinal system disorder, including reflux disease, irritable bowel disease, ulcerative colitis, constipation, diarrhea, and a migrating motor complex disorder.
... | | Method for removal of hiv from the gastrointestinal tract and bile of hiv-infected subjects and for the prevention of drug failure and prevention of development of aids in hiv-infected subjects | 20080299227 | 20081204 | | The present invention discloses a novel use of magnesium oxide and magnesium hydroxide formulation in adequate proportions and sufficient amounts to induce bowel movement to induce the excretion of HIV, along with HIV-infected pathogens present in the intestinal tract of HIV-infected persons, and to induce the excretion of HIV-loaded bile from said persons. The present invention may prevent the development of drug resistance in HIV patients undergoing drug therapy, may accelerate the recovery of HIV-infected patients, may permit full recovery of these individuals, may prevent viral mutation of patients undergoing HIV drug therapy, and may prevent the onset of AIDS in HIV-infected patients. As an additional benefit, the present invention will contribute to the prevention of adipose tissue disorders, frequently seen in persons undergoing drug therapy.... | | Monosaccharide derivatives | 20080300196 | 20081204 | | The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.
... | | Composition and method for treating digestive system disorders | 20080292693 | 20081127 | | The present disclosure provides for a novel composition, with active ingredients comprising d-Limonene and Aloe mucilaginous polysaccharides (AMPs), for the treatment of a wide variety of digestive system disorders and diseases, including conditions which affect the stomach, esophagus, bowel, colon, liver or pancreas are considered digestive system diseases and disorders, including, but not limited to, gastro-esophagus reflux disease (GERD), digestive problems such as acid reflux disease, Crohn's disease, colitis, inflammatory bowel disease (IBD), irritable bowel disease (IBS), diverticulitis, gastritis, peptic ulcers and spastic colon.
... | | Diagnosis of inflammatory bowel diseases, more particularly ulcerative colitis | 20080293625 | 20081127 | | The present invention concerns goblet cell antigen, a method for detecting antibodies directed against goblet cell antigen, a method based thereon for diagnosis of inflammatory bowel diseases and a kit for diagnosis of inflammatory bowel diseases, as well as monoclonal antibodies directed against goblet cell antigen.
... | | Lipid conjugates in the treatment of disease | 20080293672 | 20081127 | | The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof.
... | | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity | 20080293767 | 20081127 | | This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or... | | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) | 20080293776 | 20081127 | | are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat... | | 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors | 20080293782 | 20081127 | | are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat... | | Protease inhibitors for the treatment of digestive pathologies | 20080286355 | 20081120 | | The invention relates to compositions and methods for the treatment of intestinal pathologies. The invention also relates to compositions and methods which can be used to regulate the paracellular permeability of the intestinal epithelium. The inventive compositions and methods are based in particular on the use of protease inhibitors which modulate the opening of the tight junctions of the intestinal epithelium. The invention can be used for preventive or curative treatment of different pathologies, such as functional digestive disorders (FGID), in particular intestinal functional disorders (IFD) causing hyperalgesia and in particular irritable bowel syndrome (IBS), in mammals, particularly humans.
... | | Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex | 20080287371 | 20081120 | | The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds are useful as therapeutics for a range of gastrointestinal disorders, in particular those in which suppression or inhibition of the migrating motor complex (MMC) is effective or malfunction of gastric motility or increased motilin secretion is observed, such as hypermotilinemia, imitable bowel syndrome, dyspepsia, including gallbladder dyspepsia, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, acute infectious diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, functional gastrointestinal disorders, chemotherapy-induced nausea and vomiting (emesis), post-operative nausea and vomiting,... | | Pyrrolopyrimidine derivatives substituted with cyclic amino group | 20080287397 | 20081120 | | An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Prokinetic agent for bowel preparation | 20080287486 | 20081120 | | The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT4 receptor agonist as a prokinetic agent.
... | | Method of evaluating gastroparesis using an ingestible capsule | 20080287833 | 20081120 | | A method of evaluating gastroparesis comprising the steps of providing an ingestible capsule having a pH sensor and a pressure sensor, having a subject ingest the capsule, recording pH measurements from the pH sensor as a function of time as the capsule moves through at least a portion of the gastrointestinal tract of the subject, recording pressure measurements from the pressure sensor as a function of time as the capsule moves through at least a portion of the gastrointestinal tract of the subject, determining the capsule's location at a first position in the gastrointestinal tract, deriving a pressure pattern as a function of time and the pressure measurements, providing a reference pressure pattern, and analyzing the subject's pressure pattern relative to the reference pressure pattern to... | | Algorithms to predict clinical response, adherence, and shunting with thiopuriness | 20080288227 | 20081120 | | A method of using a variable set from complete blood counts and blood chemistry panels to generate a machine learned algorithm for determining the effectiveness of thiopurine treatment on inflammatory bowel disease (IBD) patients using CART, boosted trees, random forest classification, RuleFit and/or logistic regression analysis.
... | | Biaryl substituted pyrazinones as sodium channel blockers | 20080280873 | 20081113 | | Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in... | | New phenylalanine derivatives | 20080280909 | 20081113 | | wherein R1 is a methyl group and R2 is a methoxy group.
... | | Method and apparatus for virtual bowel cleaning | 20070297662 | 20071227 | | A method and an apparatus for virtual bowel cleaning are disclosed. A first CT volume data record of an area of the bowel of interest is produced, in which voxels relating to a bowel content are identified and are suitably modified in order to obtain a modified data record without visible bowel contents, which is then visualized. In at least one embodiment of the method, at least one further volume data record is produced of the area of interest, which was recorded by a CT scanner with a different spectral distribution than the first volume data record which was recorded by a CT scanner, with at least some of the voxels relating to the bowel content being identified on the basis of information about a local... | | Method of bowel cleansing | 20070298008 | 20071227 | | Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic lavages, or smaller volume hypertonic lavages.
... | | Animal nutritional supplement and method | 20070298013 | 20071227 | | The disclosed device relates to an animal nutritional supplement and more particularly to a method of using an animal nutritional supplement to reduce the incidence and effects of one or more chronic or acute conditions associated with nutritional deficiencies, gastrointestinal sand accumulation, colitis, inflammatory bowel disease, bacterial colitis, gastrointestinal pH irregularities, colonic ulcers, colonic motility deficiencies, colic, gastrointestinal fermentation deficiencies, pathological changes of certain organs in equine, and possibly even physical aging. One embodiment of the animal nutritional supplement comprises psyllium in combination with a blend of synbiotics.
... | | Method for diagnosing immunologic food sensitivity | 20070298447 | 20071227 | | The invention includes novel methodology for diagnosing immunologic food or drug sensitivities. The method for diagnosing food sensitivities includes using diagnoses of other related disorders, such as microscopic colitis or other chronic immunologic/autoimmune syndromes, chronic diarrhea, irritable bowel syndrome, and hepatitis C and other hepatic diseases, Crohn's disease, alcoholism, and other idiopathic neuropsychiatric and neurologic disorders, as indicators in the diagnosis of the food sensitivity. Additionally, failure to respond to or a relapse after treatment for microscopic colitis with bismuth subsalicylate is disclosed by the present invention as being a further indicator in the diagnosis of immunologic food sensitivity. Finally, the presence of certain HLA-DQ alleles, particularly HLA-DQ1,3; -DQ1,7; -DQ1,8; and -DQ1,9, HLA-DQ1,1, and at least two subtypes of the HLA-DQ1 allele identified by molecular analysis... | | 2-cyanopropanoic acid amide and ester derivatives and methods of their use | 20070299105 | 20071227 | | or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
... | | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists | 20070293670 | 20071220 | | has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Method and apparatus for laparoscopic retraction | 20070293728 | 20071220 | | Extraluminal and intraluminal devices and methods, and laparoscopic instrumentation, dramatically improve laparoscopic retraction of both the small and large intestine. A scaffolding external to or within a selected segment or segments of small and/or large bowel is created, allowing for the retraction of the entire selected segment or segments of bowel via grasping either the device or supported bowel wall with a laparoscopic instrument or instruments. The devices may be designed and placed in a modular fashion, with the surgeon building the final scaffolding intra-operatively, or the scaffolding may be manufactured or pre-assembled prior to intra-operative use.
... | | Monosaccharide derivatives | 20070287673 | 20071213 | | The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.
... | | Method for assessing adhesion of soils or exudates to the skin | 20070287986 | 20071213 | | Method of assessing the adhesion of soils or exudates to the skin. The method may allow for an assessment of the amount of artificial bowel movement remaining on the skin following treatment with a lotion.
... | | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | 20070280910 | 20071206 | | A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.
... | | Treatment of irritable bowel syndrome using probiotic composition | 20070280912 | 20071206 | | A method of treating irritable bowel syndrome using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.
... | | Obesity treatment tools and methods | 20070282349 | 20071206 | | Various obesity treatment tools and methods are described herein, as well as treatments for other gastric-related diseases, e.g., GERD. Treatment includes reducing the size of the stomach pouch to limit the caloric intake as well as to provide an earlier feeling of satiety. This may be done by creating a smaller gastric pouch within the stomach directly from the interior of the stomach itself. The smaller pouches may be made through the use of individual anchoring devices, rotating probes, or volume reduction devices. A pyloroplasty procedure may also be performed to render the pyloric sphincter incompetent. A gastric bypass procedure may additionally be performed using atraumatic magnetic anastomoses devices so that sugars and fats are passed directly to the bowel while bypassing the stomach. Many of... | | Diagnostic tests and methods for diagnosing inflammatory bowel disease | 20070275424 | 20071129 | | Methods are disclosed for diagnosing inflammatory bowel disease (IBD), one exemplar method of which includes determining whether a sample is positive for anti-flagellin antibodies (AFA), diagnosing the presence of IBD when the sample is positive for AFA, and diagnosing the absence of IBD when the sample is negative for AFA. Alternatively, instead of testing for positivity with respect to AFA, or in addition thereto, an exemplar method can determine whether the sample has an AFA level above an AFA cut-off value (X); and diagnosing IBD when the AFA level is above X, and diagnosing absence of IBD when the AFA level is below X. Test kits that include items used to carry out the disclosed methods are also disclosed.
... | | Salts of trimebutine and n-desmethyl trimebutine | 20070275905 | 20071129 | | Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), diabetic gastroparesis, and dyspepsia.
... | | 2-phenylpyridine derivative | 20070275950 | 20071129 | | The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.
... | | Pyrrolopyrimidine derivatives | 20070270588 | 20071122 | | has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Process and formula for treating irritable bowel syndrome | 20070264314 | 20071115 | | A process for treating irritable bowel syndrome wherein sometime before a meal, a user ingests a pill or tablet that slows down the muscles of their lower intestine that serve to push waste out from the user's digestive tract. At the same time, the user takes a fiber pill with a quantity of water. About forty five minutes after taking the aforementioned pills, the user ingests one to nine ounces, preferably three ounces, of a pecan-derived health supplement.
... | | Estrogen receptor modulators | 20070265318 | 20071115 | | The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
... | | Gastric bypass devices and methods | 20070265709 | 20071115 | | Devices and methods for achieving weight loss in obese and morbidly obese patients are disclosed. The invention combines a gastric and/or small bowel bypass (in which ingested food bypasses the stomach and, optionally, at least a portion of the small bowel) and a satiety device in the form of one or more expandable chambers, that tend to induce a feeling of satiety after the patient has consumed a relatively small amount of food. This combination of gastric and/or small bowel bypass and satiety structure may be delivered and removed using minimally invasive procedures such as an endoscope. In some instances, the gastric and/or small bowel bypass device itself can form the satiety structure. In other devices, the gastric bypass may be independent of the satiety structure... | | Lactic acid utilising bacteria and their therapeutic use | 20070258953 | 20071108 | | There is provided a method of isolating novel lactic acid utilizing bacteria from human faeces, as well as novel strains so obtained. The use of the novel lactic acid utilising bacteria in therapy, including prophylactic therapy, is described and is of particular relevance for lactic-acidosis, short bowel syndrome and inflammatory bowel disorders such as Crohn's disease and ulcerative colitis. A probiotic comprising the live lactic acid utilising bacteria is also described.
... | | N-acetylglucosamine as a food and beverage additive | 20070259094 | 20071108 | | This invention relates to the addition of N-acetylglucosamine to foods and beverages and to the use of N-acetylglucosamine as a sweetening agent. This invention also relates to foods and beverages prepared with N-acetylglucosamine and methods of preparing the same. This invention provides a preferable means of ingesting the desired daily amount of N-acetylglucosamine for its beneficial effects on the body, for example, alleviation of pain and inflammation in a patient suffering from inflammatory bowel disorder or osteoarthritis.
... | | Amorphous form of olanzapine | 20070259857 | 20071108 | | The present invention relates to an amorphous form of olanzapine Formula (I): and a process for its preparation. The present invention further relates to a pharmaceutical composition comprising an amorphous form of olanzapine (I). The pharmaceutical composition may be used, in particular, for the treatment of psychiatric, psychological or psychotic disorders, anxiety disorders, or gastrointestinal or functional bowel disorders. The present invention also relates to a method of treating said disorders.
... | | Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject | 20070259906 | 20071108 | | A method of treatment of diarrhea-predominant IBS in a subject, comprising administering a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof to achieve a plasma cilansetron concentration between about 0.1 ng/mL and about 25 ng/mL.
... | | Treatment for inflammatory bowel disease | 20070253902 | 20071101 | | A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
... | | Method for treatment of diarrhea-predominant irritable bowel syndrome | 20070254050 | 20071101 | | The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
... | | Compound ws727713 | 20070254829 | 20071101 | | The present invention relates to a new compound useful as a modulator of melanxocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, a use of the compound for manufacture of a medicament or a cosmetic for melanocortin receptor modulation, a use of the compound for manufacture of a medicament or a cosmetic for treating or preventing ishemia/reperfusion injury, brain and renal inflammatory diseases, hepatitis, sepsis/septic shock, hypoxic shock, acute respiratory distress syndrome (ARDS), rheumatic arthritis (RA), gouty arthritis, aortic regurgitation (AR), juvenile chronic arthritis, osteoarthritis, nephritis, induction of tolerance, contact... | | Chemokine receptor antagonist and medical use thereof | 20070254886 | 20071101 | | The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.
... | | Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group | 20070254898 | 20071101 | | has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | 20070254904 | 20071101 | | and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
... | | 7-amido-isoindolyl compounds and methods of its use | 20070254942 | 20071101 | | The invention encompasses 7-amido-isoindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.
... | | Use of lactobacillus salivarius | 20060292133 | 20061228 | | Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
... | | Antihuman tnf-alpha antibody activity lowering inhibitor | 20060292148 | 20061228 | | The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit preparation wherein a freeze-dried antihuman TNF-α antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-α antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.
... | | Biaryl substituted 6-membered heterocycles as sodium channel blockers | 20060293339 | 20061228 | | Biaryl substituted pyridine, pyrimidine and pyrazine compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
... | | 8-alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines | 20060293350 | 20061228 | | n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome.
... | | Method and means for improving bowel health | 20060286186 | 20061221 | | A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30%.
... | | Methods and compositions for the treatment of gastrointestinal disorders | 20060281682 | 20061214 | | The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
... | | Antibodies that specifically bind to chemokine beta-4 | 20060275210 | 20061207 | | The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis,... | | Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient | 20060275289 | 20061207 | | It is possible to use a screening system using the inhibition of CD81 gene expression, the inhibition of CD81 expression or the inhibition of its function (activity) as an indication in searching for a drug for preventing, ameliorating or treating IBD. Also, anti-CD81 antibody is highly efficacious as the active ingredient of a drug for preventing, ameliorating or treating IBD. Further, it is possible to use a polynucleotide having at least 15 consecutive bases in the base sequence of CD81 gene and/or a polynucleotide complementary to the above polynucleotide as a disease marker for IBD.
... | | Treatment of inflammation | 20060276417 | 20061207 | | This invention relates to a method of treating inflammation comprising administering to a subject in need thereof a composition comprising the inventive compounds. Also disclosed is a method of treating inflammation where the subject is suffering from a rheumatic or inflammatory bowel disease.
... | | 1,2-di(cyclic) substituted benzene compounds | 20060276465 | 20061207 | | wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH or nitrogen, and R20, R21, R22 and R23 may be the same or different and each represents hydrogen etc.
... | | Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators | 20060276542 | 20061207 | | A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
... | | Method for treating inflammation | 20060269551 | 20061130 | | A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
... | | Methods for the treatment and prevention of inflammatory diseases | 20060270630 | 20061130 | | The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.
... | | Derivatives of 4- or 5-aminosalicylic acid | 20060270635 | 20061130 | | The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.
... | | Ether derivative | 20060270693 | 20061130 | | wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.
... | | Novel derivatives of 3,3-diphenylpropylamines | 20060270738 | 20061130 | | The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
... | | Treating gastrointestinal diseases with modulators of retinoic acid | 20060263340 | 20061123 | | T cells are programmed to target the gastrointestinal tract by activation with dendritic cells capable of producing and/or transporting retinoic acid. Methods for using the programmed dendritic cells and/or T and/or B cells to treat a variety of pathogens and infectious agents residing in the intestine are also disclosed. Similarly, inhibitors of retinoic acid synthesis by dendritic cells or other cells in the gut, and inhibitors of retinoic acid receptors in T and/or B cells or other cells in the intestinal mucosa, are disclosed for treating a variety of gastrointestinal autoimmune diseases such as inflammatory bowel disease and celiac disease.
... | | Cop 1 for treatment of inflammatory bowel diseases | 20060264354 | 20061123 | | The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
... | | Sod minic multifunctional compounds for treating inflammatory bowel disease | 20060264408 | 20061123 | | The present invention relates to multifunctional compounds comprising an anti-inflammatory or immunomodulatory component, and at least one SOD mimic component capable of reacting with reactive oxygen species, and to their use in treating inflammatory bowel disease comprising ulcerative colitis and Crohn's disease. Preferred anti-inflammatory or immunomodulatory components comprise derivatives of salicylic acid and steroids.
... | | Compositions and methods of treatment for inflammatory diseases | 20060264409 | 20061123 | | Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention in a preferred embodiment is a combination of 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
... | | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | 20060264480 | 20061123 | | The present invention relates to an antagonist against vanilloid receptor and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fevescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.
... | | Methods and compositions for the treatment of gastrointestinal disorders | 20060258593 | 20061116 | | The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
... | | Compositions and methods for the treatment of inflammatory bowel disease utilizing nf-kappab decoy polynucleotides | 20060258604 | 20061116 | | Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-κB decoy polynucleotide.
... | | Amorphous tegaserod maleate | 20060258633 | 20061116 | | Provided are amorphous and purely amorphous tegaserod maleate and processes for the preparation thereof. Also provided are pharmaceutical compositions comprising amorphous or purely amorphous tegaserod maleate and methods for the treatment of irritable bowel syndrome using the same.
... | | Therapeutic agents useful for treating pain | 20060258669 | 20061116 | | where X is S or O and Ar2, R1, R2, R3, R8, n, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a “3-substituted Pyridyl Compound”), compositions comprising an effective amount of a 3-substituted Pyridyl Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a 3-substituted Pyridyl Compound are disclosed herein.
... | | Treatment and prevention of gastrointestinal disease using antagonists or partial agonists of 5ht1a receptors | 20060258732 | 20061116 | | The present invention provides a method for preventing and treating gastrointestinal diseases such as dyspepsia, irritable bowel disease and chemotherapy associated nausea by administering an antagonist or partial agonist of 5HT1A receptors.
... | | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders | 20060258735 | 20061116 | | It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
... | | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | 20060258884 | 20061116 | | 4-(methylsulfonylamino)phenyl analogues as potent vanilloid receptor antagonists and pharmaceutical compositions comprising the same. The compounds are useful as analgesics to prevent, alleviate or treat pain diseases or inflammatory disease including pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.
... | | Screw-device for anastomosis | 20060259050 | 20061116 | | The present invention, the screw-device, is a mechanical device for anastomosing hollow tube-like structures in the human body, such as blood vessels, bowels and ureters. It is thus not restricted to (micro-) vessels. It can be used in every surgical operation dealing with anastomosis and bypass operations. It allows anastomosing end to side or side to side. The screw-device is very easy to apply onto the vessel wall. Screwing is a fast technique saving operating time and requiring only basic microsurgical skills. The manufacturing is easy. Another advantage is that the screw-device can be mounted onto the receptor vessel without first opening and/or occluding this vessel. Later on, the receptor vessel wall can be opened with laser or scalpel. It should be understood that the foregoing... | | Immunomodulator | 20060252700 | 20061109 | | An immunomodulator is provided which is capable of oral intake for improvement, treatment and prevention of human immunological diseases and which is used to treat, improve and prevent human immunological diseases, especially, autoimmune diseases and allergic diseases such as hepatic cirrhosis, hepatitis, diabetes, inflammatory bowel diseases, chronic rheumatoid arthritis, asthma and cutaneous atopy, allergic diseases and cancers by a new method that can control the redox state of macrophages or monocytes, and can be incorporated into a drug, a food, a nutrient, and an infusion. The contents of oxidative glutathione and reductive glutathione in macrophages are monitored, and the ratio of oxidative glutathione and reductive glutathione is examined, whereby macrophages are classified into oxidative macrophages and reductive macrophages having different functions. The degree of progression of... |
Other Directories (alphabetical): , , , , , , , , , , , , , , , , , , , , -
###
This listing is a sample listing of patents related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.
|
